全身18F-FDG PET与18F-FDG PET/CT在疑似副肿瘤综合征患者中的诊断准确性:系统评价与Meta分析
该系统评价与Meta分析共纳入21项研究、1293例临床疑似神经或非神经副肿瘤综合征患者,评估全身18F-FDG PET或PET/CT检出潜在恶性肿瘤的诊断效能。汇总敏感度0.81(95%CI,0.76-0.86)、特异度0.88(95%CI,0.86-0.90)、诊断比值比34.03(95%CI,18.76-61.72),AUC为0.916(SE,0.018),Q*指数0.849。亚组分析中18F-FDG PET/CT特异度(0.89 vs 0.79)显著高于单独18F-FDG PET,但整体诊断性能无显著差异(AUC 0.930 vs 0.891,双侧P值0.31)。结论认为全身18F-FDG PET或PET/CT对疑似副肿瘤综合征患者检出潜在恶性肿瘤具有高诊断准确性和中等至高敏感度与特异度。
要点
- 汇总敏感度0.81、特异度0.88、诊断比值比34.03,AUC 0.916,提示诊断准确性高。
- 18F-FDG PET/CT特异度0.89显著高于单独PET的0.79,但整体AUC无显著差异。
- 纳入研究间存在中至高度异质性,排除高适用性担忧研究后AUC升至0.931。
核心结论
- 全身18F-FDG PET或18F-FDG PET/CT对疑似副肿瘤综合征患者检出潜在恶性肿瘤具有高诊断准确性、中等至高的敏感度和特异度。
研究设计与样本
- 系统检索PubMed(Medline)、Embase和Scopus(截至2016年11月)发表的相关研究。
- 以组织病理学确诊或临床随访作为参考标准,纳入21项研究、共1293例疑似副肿瘤综合征患者。
- 计算汇总敏感度、特异度和诊断比值比及95%CI,构建汇总受试者工作特征曲线并确定AUC和Q*指数。
主要发现
- 汇总敏感度为0.81(95%CI,0.76-0.86),汇总特异度为0.88(95%CI,0.86-0.90)。
- 汇总诊断比值比为34.03(95%CI,18.76-61.72),AUC为0.916(SE,0.018),Q*指数为0.849。
- 排除高适用性担忧研究后AUC为0.931(SE,0.020),诊断准确性略有提高。
- 亚组分析中18F-FDG PET/CT特异度为0.89,高于单独18F-FDG PET的0.79,差异显著。
- 18F-FDG PET/CT与单独18F-FDG PET整体诊断性能无显著差异(AUC 0.930 vs 0.891,双侧P值0.31)。
局限性
- 纳入研究间存在中至高度异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to assess the diagnostic performance of whole-body 18F-FDG PET or 18F-FDG PET/CT for detection of underlying malignancy in patients with clinically suspected neurologic and nonneurologic paraneoplastic syndromes. Methods: A systematic search was performed in PubMed (Medline), Embase, and Scopus (last updated November 2016) to identify relevant published studies reporting the performance of 18F-FDG PET or 18F-FDG PET/CT in patients with suspected paraneoplastic syndrome. Histopathologic confirmation or clinical follow-up was considered as the reference standard. Pooled estimates, with 95% confidence intervals (CIs), of sensitivity, specificity, and diagnostic odds ratio were calculated. A summary receiver-operating-characteristic curve was constructed, and the area under the curve (AUC) was determined along with the Q* index. Results: Twenty-one studies including a total of 1,293 individual patients suspected of having a paraneoplastic syndrome and who underwent 18F-FDG PET or 18F-FDG PET/CT examinations met our inclusion criteria. There was moderate to high heterogeneity among the included studies. The pooled sensitivity, specificity, and diagnostic odds ratio of 18F-FDG PET or 18F-FDG PET/CT for the detection of underlying malignancy were 0.81 (95% CI, 0.76-0.86), 0.88 (95% CI, 0.86-0.90), and 34.03 (95% CI, 18.76-61.72), respectively. The AUC and the Q* index were 0.916 (SE, 0.018) and 0.849, indicating excellent diagnostic accuracy. The diagnostic accuracy was slightly improved after studies with high applicability concerns were excluded (AUC, 0.931; SE, 0.020). In a subgroup analysis, 18F-FDG PET/CT was found to have a significantly higher specificity (0.89 vs. 0.79) than 18F-FDG PET alone, with no evidence of significant difference in the overall performance (AUC, 0.930 vs. 0.891; 2-tailed P value for difference, 0.31). Conclusion: This meta-analysis of available studies demonstrates that whole-body 18F-FDG PET or 18F-FDG PET/CT has high diagnostic accuracy and moderate to high sensitivity and specificity for detection of underlying malignancy in patients suspected of having a paraneoplastic syndrome.
引用
- Sheikhbahaei S, Marcus CV, Fragomeni RS, et al. Whole-Body 18F-FDG PET and 18F-FDG PET/CT in Patients with Suspected Paraneoplastic Syndrome: A Systematic Review and Meta-Analysis of Diagnostic Accuracy. J Nucl Med. 2016. PMID: 27980049. doi:10.2967/jnumed.116.183905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。